Research and Practice in Thrombosis and Haemostasis

Article	Citations
Editorial Board	58
von Willebrand factor, ADAMTS-13, and thrombospondin 1 in relation to clinical outcomes in elderly patients with a recent myocardial infarction	56
Uncertainties on the prognostic value of admission D‐dimer on venous thromboembolism occurrence in patients with COVID‐19	49
Issue Information	48
Letter in response to Colpani et al “A comparative study in type 2 von Willebrand disease patients using four different platelet-dependent von Willebrand factor assays”	44
Factor V Leiden interferes with protein S activity assay	41
How We Write a Manuscript Discussion	39
Editorial Board	35
Reply to “Comment on: A comparative study in type 2 von Willebrand disease patients using four different platelet-dependent von Willebrand factor assays”	33
Impact of antiplatelet therapy on hemostatic plug formation in the setting of thrombocytopenia	32
Thrombotic potential during pediatric acute lymphoblastic leukemia induction: Role of cell‐free DNA	31
Transmembrane thiol isomerase TMX1 counterbalances the effect of ERp46 to inhibit platelet activation and integrin αIIbβ3 function	28
How to use and report data on D‐dimer testing in the COVID‐19 era?	27
Issue Information	25
Measuring the impact of hemophilia on families: Development of the Hemophilia Family Impact Tool (H‐FIT)	25
Risk of venous thromboembolism in pediatric hospitalized patients undergoing noncardiac surgery: A report from the Children's Hospital‐Acquired Thrombosis consortium	24
Properdin (factor P) as a new target cleaved by factor XIa: Intrinsic coagulation at the crossroads with inflammation	23
Impact of oral anticoagulant choice for the secondary prevention of venous thromboembolism on the risk of inpatient bleeding	22
Issue Information	22
Antithrombotic treatment switching in elderly patients with atrial fibrillation and the risk of thromboembolism, bleeding, and cardiac death	22
Comparison of novel thrombin generation methods with established techniques is mandatory	22
Thrombo‐inflammatory biomarkers and D‐dimer in a biracial cohort study	22
Current practices in pediatric hospital‐acquired thromboembolism: Survey of the Children's Hospital Acquired Thrombosis (CHAT) Consortium	21
	20
	19

	19
	19
Blocking domain 6 of high molecular weight kininogen to understand intrinsic clotting mechanisms	18
Stability of specimens for use in the Centers for Disease Control and Prevention assays for factor VIII and IX inhibitors	17
Risk factors for neurologic sequelae in children and adolescents with hemophilia after intracranial hemorrhage	17
Identification of von Willebrand factor D4 domain mutations in patients of Afro‐Caribbean descent: In vitro characterization	16
Inhibitor development upon switching from plasma-derived to recombinant factor VIII in previously untreated patients with severe hemophilia A: the PUP-SWITCH study	16
Plasma microRNA-145-5p as a diagnostic biomarker for acute deep vein thrombosis	16
RPTH announces annual Editor’s Award recipients for 2023	16
Primary thromboprophylaxis in ambulatory symptomatic patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials	16
Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA‐LEA noninterventional studies	15
RPTH year 6 article collection	15
Revisiting important issues in cancer and atrial fibrillation	15
Factor eight inhibitor bypassing activity for refractory bleeding in coronary artery bypass grafting: A propensity‐matched analysis	15
Use of rotational thromboelastometry to predict hemostatic complications in pediatric patients undergoing extracorporeal membrane oxygenation: A retrospective cohort study	14
Aspirin thromboprophylaxis in joint replacement surgery	14
A systematic review of biomarkers among hospitalized patients with COVID‐19 predictive of venous thromboembolism: A communication from the Predictive and Diagnostic Variables Scientific and Standardiz	14
Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1–3	13
PB0965 Delphi Survey of Canadian Physicians to Determine Optimal Anticoagulant Treatment Approaches for Patients with Cancer and Splanchnic Venous Thrombosis	13
Thromboelastography and thrombin generation assessments for pediatric severe hemophilia A patients are highly variable and not predictive of clinical phenotypes	13
Carbamazepine, phenytoin, and oral anticoagulants: Drug‐drug interaction and clinical events in a retrospective cohort	13
Pseudohomozygous dysfibrinogenemia	13
Hormonal therapies in females with blood disorders: thrombophilia, thrombosis, hemoglobinopathies, and anemias	13
PB0165 Gene Correction of Human Hemophilia B Mutation by PAM-Flexible Cas9-Mediated Base-Editing Approach	13
PB0182 Development of a Non-Viral Gene Therapy Approach for Severe Bleeding Disorders	12
PB0191 myGTR: A Patient Engagement Tool from the World Federation of Hemophilia Gene Therapy Registry	12
PB0201 Efanesoctocog Alfa Versus Extended Half-Life Factor VIII Therapies for Prophylaxis in Adolescents and Adults with Severe Hemophilia A: A Matching-Adjusted Indirect Comparison and Meta-Analysis	12
PB0192 Novel Patient-Directed Learning in the Era of Novel Therapies	12
PB0178 Factor X Enhances the Coagulant Potentials of Emicizumab	12
PB0186 Results from BeneGene-1 Study: Prospective Collection of Bleeding Rate in Hemophilia B Patients Prior to Phase 3 Study (BeneGene-2) of Fidanacogene Elaparvovec	12
PB0189 Knowledge and Attitudes of Haemophilic Patients Toward Gene Therapy	12
PB0170 Evaluation of the Extended-Half Life FVIII Products' Measurement Accuracy and Precision With Five Different Types of Laboratory Assays	12
PB0184 Ultrasound Mediated Delivery of CRISPR/Cas9 Plasmid in Hemophilia A Mice Shows Therapeutic levels of FVIII Following NHEJ Gene Editing	12
PB0193 Financial Impact of Switching to Emicizumab from Conventional Haemostatic Agents in Acquired Haemophilia A	12
PB0197 Efficacy of Adjusted Weight-Based Dosing of DDAVP in Type 1 von Willebrand Disease	12
PB0208 Spleen Rupture in Afibrinogenemia: Hemorrhagic or Thrombotic	11
PB1003 The Factor V HR2 Haplotype and the Risk of Venous Thromboembolism (VTE): A Single Center Study	11
PB1020 Simultaneous Generation of Thrombin and Plasmin in Patients with Deep Vein Thrombosis and High Levels of Lipoprotein (a)	11
PB0238 Prospective, Phase III Study of the Efficacy, Safety, and Pharmacokinetics of a Human Antithrombin III Concentrate in Congenital Antithrombin Deficiency during Surgery or Childbirth	11
PB0209 Clinical Manifestations of Patients with Congenital Dysfibrinogenemia with the Most Common Hotspot Mutation in FGA Gene p.Arg35His	11
PB1010 Exercise Could Reveal Pulmonary Vascular Abnormalities in Patients with Chronic Thromboembolic Pulmonary Disease - A Hemodynamic Study	11
PB1021 Using an Age and Fibrinogen Levels Adjusted D-Dimer Cutoff Significantly Improves the Specificity of D-Dimer Testing for Excluding Pulmonary Embolism	11
PB1015 Venous Thromboembolism in Patients with Newly Diagnosed Lymphoma and Its Association with ThroLy and Khorana Risk Scores	11
PB0206 Isolated Prolongation of APTT with Abnormal Bleeding Phenotype due to Intrinsic Tenase Defect - A Case Series	11
PB0998 Clinical Performance Evaluation of New Stago Systems for Protein S Levels Determination: sthemO PS Clot and sthemO PS Free on sthemO 301 Analyzer	11
PB0993 Thromboelastometry (ROTEM) in Detection of Hypercoagulability in Patients Referred for Thrombophilia Screening	11
PB1033 Delphi Consensus Recommendations for Neuraxial Anesthesia in Adults with Platelet Disorders and Coagulation Defects	11
PB0286 Population Pharmacokinetics and Pharmacodynamics of Bivalirudin in Children on Ventricular Assist Device Support	10
PB0299 Surface Modification of Lung Assist Device for Neonates by Dual-Modification with Antithrombin-Heparin (ATH) and Tissue Plasminogen Activator (t-PA)	10
PB1078 Severe Thromboembolic Events in A Patient with Protein C and Protein S Heterozygous Deficiencies	10

PB0235 Phase 3 Study of the Efficacy, Pharmacokinetics, Immunogenicity and Safety of von Willebrand Factor/Factor VIII Concentrate in Patients with Severe von Willebrand Disease under 6 Years of Age	10
PB1053 Protective Role of the SerpinE2 PN-1 in Renal Disease	10
PB1071 A Single-Domain Antibody Enhancing Protein S Activity Reduces Vaso-Occlusion in a Murine Model of Sickle Cell Disease	10
PB1081 Identification of Related Molecular Biological Effects on Two Novel Point Mutations in Inherited Antithrombin Deficiency	10
PB0289 Association of Elevated Coagulation Factors VIII, IX and XI with Recurrent Thrombotic Events in Children with Non-Central Venous Line Deep Vein Thrombosis	10
PB0269 Health-Related Quality of Life of, and Burden of Caring for, Thai Patients with Hemophilia Using the Canadian Hemophilia Outcomes-Kids' Life Assessment Tool v3.0 and Hemophilia Family Impact To	10
PB1047 A Patient with Severe, Refractory ITP and GI Bleeding is kept Hemodynamically Stable over Days with a Combination Therapy of Tranexamic Acid, Recombinant FVIIa, F XIII and Red Blood Cell Concen	10
PB0260 Immune Complex-Mediated Acquired von Willebrand Syndrome in a 5-year-old Boy after Allogeneic Hematopoietic Stem Cell Transplantation	10
PB1077 A Novel C238G, PROC Mutation in Patients with Thromboembolism, Causes Intracellular Protein Retention	10
PB1090 Modelling the Effects of 4-Factor Prothrombin Complex Concentrate for the Management of Factor Xa Inhibitor-Associated Bleeding	10
PB0287 Thromboembolic and Hemorrhagic Events in Pediatric Patients Assisted with Mechanical Circulatory Support and Bivalirudin Anticoagulation: A Retrospective Observational Study	10
PB0249 Some Coagulation Profiles (PT, APTT, TT, FIB), Red Cell, Total White Cell, Platelet Counts and Their Indices Activity Levels in Persons Exposed to Wood Smoke (Firewood) in Calabar, Nigeria	10
PB1060 Thrombin Generation and Fibrin Clot Structure in Nephrotic Patients with Primary Glomerular Disorders	10
PB0295 Off-Label Use of Rivaroxaban in the Management of Three Cases of Pediatric Arterial Ischemic Stroke	10
PB0464 Smaller Nadroparin Dose Reductions Required for Patients with Renal Impairment: A Multicenter Study	9
PB0886 Novel Small-Molecule Inhibitors of Clot Retraction and Thrombin- Induced Platelet Aggregation, That Do Not Inhibit PAR-1-Induced Platelet Aggregation	9
PB0856 Time Course of Thrombocytopenia during DDAVP Test in a Boy with a De Novo c.4121G>A ( p.Arg1374His) Variant of the VWF Gene	9
PB1132 Comparison of Thrombophilia Assay Results for the ISTH/SSC Plasma Standard from Different EQA Providers – Data from the EQATH Group	9
PB1106 A 2-min 30 sec at 4500g Centrifugation or a 11-min at 2500g are Comparable on 13 Coagulation Assays	9
PB1103 Clinical Performance Evaluation of the New Stago Systems for APTT Determination: sthemO PTTA and sthemO CK Prest on sthemO 301 Analyzer	9
PB0867 Alpha-2-Macroglobulin Precludes Platelet Aggregation in Response to the Brain-Derived Neurotrophic Factor (BDNF)	9
PB0858 Evaluation of Automated Chemiluminescent von Willebrand Factor Assays in the Diagnosis of von Willebrand Disease	9
PB1220 DNase-1 Overcomes Thrombolytic rT-PA Resistance of Platelet-Rich Ischemic Stroke Thrombi	9
PB0902 The Effect of Hypercortisolism on Platelet Function in Dogs with Cushing's Syndrome	9
PB0884 Development of a Platform to Study Thrombogenicity of Clinically- Used Stents	9
PB0333 Therapeutic Plasma Exchange-Related Complications in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura	9
PB1117 Congenital Thrombotic Thrombocytopenic Purpura: Identification of Two Heterozygous Mutations in Splice Sites through NGS Sequencing	9
PB0308 Anticoagulation Monitoring of UFH (Unfractioned Heparin) in a Pediatric Patient during Long Term ECMO (Extracorporeal Membrane Oxygenation)	9
PB0300 Diagnosis of Thromboembolism in Children with Cancer: Validation of Diagnostic Algorithms Using Real-World Data	9
PB0866 Glycoprotein VI: An Interesting Target to Prevent Early Stent Thrombosis?	9
PB1226 Acquired Haemophilia A in Finland: A Nationwide Study of Incidence, Treatment and Outcomes	9
PB0455 Bilateral Asynchronous Adrenal Infarction in JAK2-Positive Essential Thrombocythemia	9
PB0896 Time-and Distance-Resolved Robotic Imaging of Fluid Flow in Vertical Microfluidic Strips: A New Technique for Quantitative, Multiparameter Global Measure of Haemostasis	9
PB0900 Developing Standards to Support Platelets and Platelet Components	9
PB0330 Relevance of ADAMTS13 Antigenic Levels in the Characterization of Pathological Mechanisms Associated with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP)	9
PB1125 Qualitative and Quantitative Assessment of Direct Oral Anticoagulants (DOACs) in Routine Clinical Practice	9
PB0301 Ocular Vein Occlusion in Pediatrics: Should Thrombophilia Investigation and Anticoagulant Treatment be Initiated?	9
PB1116 Applications of DOAC Removal in the Laboratory	9
PB0883 Defining the Role of Hepcidin and Ferroportin Interactions in Regulating Platelet Function	9
PB1218 Aptamer Inhibitor of Von Willebrand Factor Induces Thrombolysis and Improves Vascular Patency Upon Immediate and Delayed Treatment in a Microfluidic Model of Stroke	9
PB1245 Efficacy, Safety and Dosing of Pasteurized Plasma-Derived von Willebrand Factor/Factor VIII Concentrate for the Treatment of von Willebrand Disease: A Systematic Review	8
PB1273 Inhibitor Recurrence on Emicizumab Prophylaxis in Tolerized Patients with Severe Hemophilia A	8
PB1290 Successful Very Low Dose Immune Tolerance Induction with Albutrepenonacog Alfa in a Severe Hemophilia B Child with Anaphylactic Reaction to Factor IX	8
PB0534 Rapid Measurement of DOAC Concentration and Platelet Function Using Whole Blood in a Disposable Microfluidic Device	8
PB0477 Safety and Efficacy of Direct Oral Anticoagulants in Patients with Chronic Thromboembolic Pulmonary Hypertension	8
PB1249 Prospective, Observational Study of the Clinical Characteristics of Adults and Adolescents with Severe Hemophilia A	8
PB0533 New Low Molecular Weight Heparin Antidote Based on an Antithrombin Mutant	8
PB1300 Intramural Hematoma of Gastrointestinal Tract in People With Hemophilia: A Pooled Study	8
PB0542 Investigating Thrombin-Loaded Fibrin in Whole Blood Clot Microfluidic Assay via Fluorogenic Peptide	8
PB1254 A New Tool to Assist in Treatment Selection - The World Federation of Hemophilia (WFH) Shared Decision-Making (SDM) Tool	8
PB0478 Safety and Efficacy of Rivaroxaban as Extended-Phase Anticoagulation in Patients with Cancer and Venous Thromboembolism: A Preliminary Data Analysis from the MAC Project	8
PB0480 Tinzaparin Safety in Patients with Severe Renal Impairment	8
PB0527 Assessment of the Rats Model of Hemophilic Arthritis by Micro CT Scanning	8
PB1301 Low-Titer Inhibitor and Decreased FVIII Activity to 1.1% with Increased Bleeding in a 4 Year Old Patient with Congenital Mild Hemophilia A	8
PB1275 Multicenter and Cross-Sectional Study of Joint Damage of Patients with Non-Severe Hemophilia: A “Mediterranean Group” Study	8
PB1228 Inhibitor Detection in Acquired Hemophilia A: A Comparison between the Nijmegen Modified Bethesda Assay and an Anti-FVIII ELISA	8
PB1344 Impact of Spleen Tyrosine Kinase Inhibition on Vaccine-Induced Thrombotic Thrombocytopenia Antibody-Induced Procoagulant Platelet and Thrombus Formation	7
PB0562 Effects of High-Fat and High-Carbohydrate Meals on Coagulation and Anticoagulation Factors and Lipid Profile	7
PB1357 Addition of Platelet Factor 4 in the Heparin-Induced Platelet Activation (HIPA) Test for the Diagnosis of Heparin Induced Thrombocytopenia (HIT): Results from a Restrospective Monocentric Study	7
PB1329 Retrospective Study of the Effectiveness and Safety of the Use of rIX- FP in Patients with Haemophilia B. Experience of Four Centres in the Region of Castilla y León	7
PB1370 Thrombocytosis and Acquired Bleeding Disorders in Patients with Myeloproliferative Neoplasms	7
PB1411 Study of Endothelial Dysfunction in Patients with Unprovoked Venous Thromboembolism through Endothelial Colony-Forming Cell In Vitro Characterization	7
PB1390 Gray Platelet Syndrome- Novel NBEAL2 Pathogenic Variants and Hemostasis Evaluation by Global Coagulation Assays	7
PB1402 NBEAL2 and the Intragranular Proteoglycan, Serglycin, Both Contribute to the Initiation and Progression of Aortic Aneurysms	7
PB1378 Complex Phenotypic Expression of an ADP Receptor (P2Y12) Defect in Greater Swiss Mountain Dogs	7
PB0625 Emicizumab Prophylaxis in People with Hemophilia A Aged >50 Years withComorbidities:ExperienceFromtheATHN7Hemophilia Natural History Study	7
PB1359 Fc Modified KKO Blocks Thrombosis in Heparin-Induced Thrombocytopenia (HIT), But not in Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT)	7
PB1352 A Survey on Anticoagulation in Patient with ITP	7
PB0566 Prediction and Validation of the Effects of Targeting either Coagulation FXI Activation or Activity on Thrombin Generation	7
PB0551 A Comparison of USP Potency Adjusted and Mass Adjusted Heparins of Bovine, Ovine, and Porcine Origin in Various Assays	7
PB1314 Risk Assessing Medical Inpatients for Bleeding Events: The Medical Inpatients Thrombosis and Hemostasis (MITH) Study	7
PB0594 Factor XI Localization in Human Deep Venous Thrombus and Function of Activated Factor XI on Mural Thrombus Formation Under Low-Shear Condition	7
PB1140 Laboratory Features and Genotype of a Family with Heritable Dysfibrinogenaemia (HD)	7
PB1405 Development of a Method for the Detection of the JAK2V617F Mutation in Human Circulating Endothelial Cells	7
PB0634 A Phase 3, Single-Arm, Multicenter, Open-Label, One-Way Crossover Study to Evaluate the Efficacy and Safety of Fitusiran Prophylaxis in People with Severe Hemophilia A or B, with or without Inh	7
PB0622 A Report of the Measurement of Steady State Emicizumab Levels in an Irish Cohort of Persons with Severe Haemophilia A	7
PB1376 Periprocedural Hemostatic Outcomes in Bleeding of Unknown Cause	7
PB0590 The Control of Protein Binding on Bio-Interface by a Novel Coating to Prevent Contact Activation on Biomaterials	7
PB1348 Thrombopoietin Receptor Agonist and Rituximab Combination Therapy in Patients with Refractory Primary Immune Thrombocytopenia. A Single-Center Study	7
PB1317 Assessment of the Combined Effects of Emicizumab and Fitusiran with In Vitro Spiking of Emicizumab and Simulated Fitusiran into Factor VIII Deficient Plasma Using Thrombin Generation Assay	7

PB1315 Weight-Band Dosing with Mim8: Using Modelling to Support a Streamlined Approach to Haemophilia A Treatment	7
PB0532 The Factor XIa Antibody Osocimab Combined with Enoxaparin Strongly Inhibits Clotting in Extracorporeal Circuits in vitro	7
PB0612 COVID-19: Predictive Value of Methemoglobinemia	7
PB0664 Treatment Adherence in Young People with Hemophilia: Perceptions of UK Healthcare Professionals	7
PB0589 Human Transthyretin (hTTR) Amyloid Fibrils Induce Plasma Clotting by Activating the Intrinsic Pathway of Blood Coagulation: Implications in the Pathogenesis of hTTR Intracardiac Thrombosis	7
PB0627 Management of Invasive Procedures in Patients with Hemophilia A Receiving Emicizumab Prophylaxis: Real-World Data from a National Hemophilia Treatment Center	7
PB1385 Developing a Stem Cell-Based Model for Glanzmann Thrombasthenia to Explore VWF-GPIb Axis during Megakaryopoeisis	7
PB1381 Value of Next-Generation Sequencing in the Diagnosis of Platelet Function Disorders	7
PB1332 Heightened Thrombosis in Immune Thrombocytopenia: Insights into the Risk Factors and Clinical Outcomes from an Australian Hospital Cohort	7
PB0586 Protein S Deficiency is Associated with an Increased Risk of Deep Vein Thrombosis in Pregnant Women Using Oral Contraceptive	7
PB0387 Characterising the Molecular Pathways Controlled by ETV6 during Megakaryopoiesis	6
PB0412 Simulating the Impact of Thrombin on Platelet Function Requires Simultaneous Activation of Both PAR-1 and PAR-4	6
PB0376 Vacuolar-Type ATPase Dependent Acidification of Megakaryocyte and Platelet α-Granules Maintains Packaging of VWF	6
PB1429 NETs Promote Gasdermin-D-Dependent Pulmonary Thrombosis in Mice Exposed to Cigarette Smoke and Flu	6
PB0347 Argatroban or Bivalirudin for Suspected or Confirmed Heparin Induced Thrombocytopenia at a Large Academic Medical Center	6
PB1204 Synergistic Role in Accelerating Clot Formation and Fibrin Polymerisation of Cancer Cells and Platelets: a Thromboelastometric Study	6
PB1142 A Rapid Centrifugation 4000 g, 4 min Does not Impact Routine Coagulation Assays	6
PB1189 Concentrations of Direct Oral Anticoagulants Acting as FXa Inhibitors Could not be Accurately Determined in Patients Treated with Therapeutic Doses of Low Molecular Heparin as Bridging Therapy	6
PB0397 Differential Requirement for Ligand Valency in the Activation of CLEC-2 in Human and Humanised Mouse Platelets	6
PB0386 Increased Platelet Expression of the Transcriptional Suppressor ETV6 Can Be Detected by Immunofluorescence on the Blood Smear and Associates with ETV6-Related Thrombocytopenia	6
PB1441 The Risk of Recurrent Venous Thromboembolism of Patients with Homozygous or Double Heterozygous Factor V Leiden and/or Prothrombin G20210A Mutation: A Prospective Cohort Study	6
PB0369 New Insights into the Formation of Platelets (Thrombopoiesis) from Infused Megakaryocytes (Mks) into Mice	6
PB1431 Effect of Allele-Selective Silencing of von Willebrand Factor in Mice on Experimental Bleeding and Thrombosis Models	6
PB0349 Anti-PF4-Antibodies in Patients Suspected of Vaccine-Induced Immune Thrombotic Thrombocytopenia After SARS-CoV-2 Vaccination	6
PB1203 The Influence of Human Immunodeficiency Virus Infection and Antiretroviral Therapy on Plasma Clot Properties in a Group of Black South African Women	6
PB0403 A Common Variant in GRK5 Reveals a PAR1-Specific Regulation in Platelets	6
PB1208 Thrombin Activatable Fibrinolysis Inhibitor Dependent Effects on Whole Blood Clot Formation and Lysis Dynamics Across the Peripartum Period	6
PB0352 Non-Pathogenic Anti-PF4 Antibodies after SARS-CoV-2 Vaccines: Long Term Follow-Up	6
PB1166 The True Effect of Haemolysis Interference on Routine Coagulation Tests Using Paired Matched Samples Performed on the Sysmex CN-Series Coagulation Analyser	6
PB0669 Final Analysis of Long-Term Clinical Outcomes of Recombinant Factor IX Fc Fusion Protein Prophylaxis in Adults ≥50 Years with Severe Hemophilia B	6
PB1160 Detection of Drug-Induced Platelet Inhibition with Sonic Estimation of Elasticity via Resonance Using the QuantraTM: An Observational invitro Study with Healthy Volunteers	6
PB1447 Factor V Leiden: An Independent, Gender-Dependent Risk Factor for Venous Thromboembolism	6
PB1143 Analytical Performance Evaluation of a New Stago System SthemO 201	6
PB0444 Residual Pulmonary Vascular Obstruction is Associated with Prothrombotic Fibrin Clot Phenotype in Patients Following Pulmonary Embolism	6
PB0358 Hereditary Bleeding Disorders Web-Based Registry of Patients with Inherited Platelet Disorders	6
PB0429 Potential Difference in Platelet Aggregation between Clinical Dexmedetomidine and Experimental Medetomidine Due to Dose Differences	6
OC 05.2 Impact of Heparin on Disease State Transition in Hospitalized, Non-Critically Ill Patients with COVID-19; Secondary Analysis of an International Multi-Platform RCT	5
PB1510 Circulating Extracellular Vesicles and Neutrophil Extracellular Traps Contribute to Endothelial Dysfunction in Pregnant Women with Preeclampsia	5
OC 02.1 Dose-Dependent Elimination of HPA-1a Platelets by Subcutaneous RLYB212, a Monoclonal Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia	5
PB1498 Risk of Venous Thromboembolic Disease and Adequacy of Prophylaxis in Hospitalized Cancer Patients in Uruguay	5
LB 02.4 Anti-Platelet Factor 4 Induced Immunothrombosis Independent of Heparin or Vaccination	5
HTRS2023.O6B.2 Allosteric regulation of coagulation factor IXa	5
Editorial Board	5
PB1463 Clinical Predictors of In-Hospital Mortality in Patients with Acute Pulmonary Embolism: 15-Years Experience in a Single Center in Argentina	5
PB1465 Venous Thromboembolism in Hospitals Belonging to APHP: A Retrospective Cross-Sectional Study Using the Hospital Discharge Database (PMSI) from Clinical Data Warehouse	5
PB1453 Clinical Course and Long-Term Outcomes of Cerebral Venous Sinus Thrombosis in Asians	5
PB1476 Occurrence of Hospital-Associated Thrombosis Despite Thromboprophylaxis in the Setting of Current Thromboprophylaxis Strategies: An Observational Cross-Sectional Study	5
HTRS2023.P3.2 Clinical outcomes in patients with acute hepatic porphyria treated with givosiran who stopped hemin prophylaxis at study entry: post hoc analyses from the phase 3 ENVISION study through	5
HTRS2023.P2.20 Common documentation errors in the electronic health records of persons with hemophilia B	5
OC 09.4 C1-Inhibitor Levels and Venous Thromboembolism: Results from a Mendelian Randomization Study	5
PB1511 Systematic Review on Hemostatic Biomarkers Predictive for Postpartum Hemorrhage	5
OC 05.3 Incidence and Risk Factors for Venous Thromboembolism in Hospitalized Patients Across Three Major COVID-19 Variants in an Asian Cohort	5
PB1505 C-Reactive Protein Across the Menstrual Cycle in Females with Sickle Cell Disease	5
OC 03.2 Characterization of Peripheral Monocyte Subsets in a Prospective Cohort of Patients with Acute Stroke Suspicion: Results of BOOST Study	5
PB1500 In-Hospital Vein Thromboembolism Prevention in Patients with Atrial Fibrillation	5
LB 01.3 Factor XIII 24-Hour Trajectory Analysis in Severely Injured Patients: Post-hoc Analysis of the Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) Study	5
PB0727 The Role of Thrombin and Thrombin Signaling in Chronic LCMV Infection	5
HTRS2023.P4.14 Using heparin-calibrated assays to estimate anti-factor Xa activity of factor Xa inhibitors: correlation analysis of published data	5
PB0713 Increased Tissue Factor mRNA Expression is Associated with High Plasma Levels of Activated Factor VII-Antithrombin Complex and Predicts Mortality in Primary Liver Cancer	5
PB0698 Determinants of Desmopressin Response in Bleeding Disorders: a Systematic Review and Meta-Analysis	5
HTRS2023.P2.1 Will my patient bleed? Management and outcomes for patients with severe FXI deficiency	5
HTRS2023.P2.18 Pediatric persons with hemophilia A on EHL-FVIII or emicizumab prophylaxis require iron therapy despite low annualized bleeding rate	5
OC 18.1 The Role of Mitochondrial Calcium Uniporter in Platelet Function	5
OC 14.2 Pharmacokinetic Characteristics of ADAMTS13 in Patients with Congenital Thrombotic Thrombocytopenic Purpura: Interim Results from a Phase 3 Randomized, Controlled, Open-Label, Crossover Study	5
OC 06.4 Therapeutic Efficacy of aNovel Humanized anti-ADAMTS13 Antibody to Treat Left Ventricular Assist Device-Induced Acquired Von Willebrand Syndrome	5
PB0729 Thrombophilia in Patients with Acute Viral Infections of the Respiratory Tract	5
OC 15.4 ADAMTS13 Results for the SSC Plasma Standard from ECAT and UK NEQAS External Quality Assessment Programmes	5
PB1503 Significant Effect of Hormonal Contraception on Venous Thromboembolism Risk in Women with Sickle Cell Disease, but is Estrogen the Culprit?	5
LB 01.2 Emicizumab Prophylaxis Instead of Immunosuppressive Therapy in Patients with Acquired Hemophilia A (AHA)	5
PB1486 Quality of Anticoagulation Management in Patients Receiving Warfarin at Private Cardiac Centers in Addis Ababa, Ethiopia	5
LB 02.1 Extending Venous Thromboembolism Secondary Prevention with Apixaban in Cancer Patients. The EVE Trial	5
PB1471 Age- and Sex Specific Risks of Major Cardiovascular Complications and Death following Elective Hip and Knee Arthroplasty in the Netherlands: A Dutch Hospital Data Registry Study	5
OC 02.3 OC 02.3 Risk Factors for Severe Postpartum Hemorrhage after Assisted Reproductive Technology: Data from the French HEMOTHEPP Cohort Study	5
PB0715 H3 Alters the Behavior of Endothelial Cells In Vitro	5
PB0694 A Chemiluminescent-Based Multiparameter Platform for Simultaneous Measurement of Factor VIII Activity and Thrombin Generation	5
PB0679 Clinical Characteristics and Disease Outcomes in Previously Treated Patients with Haemophilia: Results from a Real-World Study in Europe and United States	5
LB 02.3 Targeted Thromboprophylaxis in Patients with Lower Limb Trauma Requiring Immobilization : Stepped Wedge Randomized Trial	5
OC 14.4 Recombinant ADAMTS13 Prophylaxis in Patients with Congenital Thrombotic Thrombocytopenic Purpura: Interim Analysis from Phase 3B Continuation Study	5
OC 12.1 First Evidence of Improvement of Long-term Joint Outcomes through Ultrasound for Hemophilia; from 3-Years Prospective J-DaUPHIN Study	5
OC 31.3 Phase 1 Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VMX-C001 in Healthy Subjects	4
OC 32.2 Risk of Venous Thromboembolism and Major Bleeding in Patients with Acute Medical Illness Receiving Thromboprophylaxis with Enoxaparin	4
PB0827 WFH World Bleeding Disorders Registry Launches the First Global Data Collection on People with von Willebrand Disease	4
PB0843 The Alarming Persistence of Heavy Menstrual Bleeding in Persons with Inherited Bleeding Disorders Managed in Hemophilia Treatment Centers	4
PB0838 Association between Hemoglobin Values and VWF Assays: A Multi-Center Investigation	4
OC 28.2 Neutrophil-Derived Factor XIII-A Transglutaminase Contributes to Adipose Tissue Fibrosis and Inflammation in Mouse-Obesity Model	4
PB0052 Heparin Type & Clinical Outcomes in Hospitalized, Non-Critically Ill Patients with COVID-19: Secondary Analysis of an International Multi-Platform RCT	4
OC 31.4 Novel Factor Xa agents that Restore Hemostasis in Mice Treated with Apixaban	4
PB0850 Management of Type 2M von Willebrand Disease in Lower Limb Surgery	4
OC 25.5 Endothelial Damage and Complement Dysregulation in Fetuses from Mothers with Preeclampsia	4
OC 30.5 Expression and Activity of Human Factor VIII (hFVIII) Following Single and Repeat Administration of an Integrating Non-Viral Gene Therapy in Multiple Mouse Models of Severe Hemophilia A	4
OC 37.3 Increased Concentrations of Lipoprotein (a) as a Factor Enhancing Hypofibrinolysis in Patients with Severe Aortic Stenosis	4
OC 32.4 Predictors of Venous Thromboembolism Chemoprophylaxis in Hospitalized Medical Patients: The Medical Inpatients Thrombosis and Hemostasis (MITH) Study	4
Author Index	4
Author Index	4
OC 28.1 Released, but Not Platelet-associated FXIII-A, is Associated with Crosslinking Activity Exposed on the Platelet Membrane	4